HRP20190289T1 - Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba - Google Patents
Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotrebaInfo
- Publication number
- HRP20190289T1 HRP20190289T1 HRP20190289TT HRP20190289T HRP20190289T1 HR P20190289 T1 HRP20190289 T1 HR P20190289T1 HR P20190289T T HRP20190289T T HR P20190289TT HR P20190289 T HRP20190289 T HR P20190289T HR P20190289 T1 HRP20190289 T1 HR P20190289T1
- Authority
- HR
- Croatia
- Prior art keywords
- stemic
- antigenes
- prostate
- stations
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118022.6A DE102011118022B4 (de) | 2011-06-30 | 2011-06-30 | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| EP12729996.4A EP2726507B1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
| PCT/EP2012/062716 WO2013001065A1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190289T1 true HRP20190289T1 (hr) | 2019-05-03 |
Family
ID=46384405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190289TT HRP20190289T1 (hr) | 2011-06-30 | 2012-06-29 | Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9200078B2 (enExample) |
| EP (2) | EP3505536B1 (enExample) |
| JP (4) | JP2014528696A (enExample) |
| AU (1) | AU2012277784B2 (enExample) |
| CY (1) | CY1121249T1 (enExample) |
| DE (1) | DE102011118022B4 (enExample) |
| DK (1) | DK2726507T3 (enExample) |
| ES (2) | ES2989975T3 (enExample) |
| HR (1) | HRP20190289T1 (enExample) |
| HU (1) | HUE042008T2 (enExample) |
| LT (1) | LT2726507T (enExample) |
| PL (1) | PL2726507T3 (enExample) |
| PT (1) | PT2726507T (enExample) |
| RS (1) | RS58448B1 (enExample) |
| SI (1) | SI2726507T1 (enExample) |
| SM (1) | SMT201900085T1 (enExample) |
| TR (1) | TR201901991T4 (enExample) |
| WO (1) | WO2013001065A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| AU2021276327A1 (en) * | 2020-05-19 | 2022-12-01 | City Of Hope | Engineered anti-prostate stem cell antigen fusion proteins and uses thereof |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2024233662A2 (en) * | 2023-05-09 | 2024-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to psca polypeptides |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| CN121673412A (zh) * | 2024-09-12 | 2026-03-17 | 上海医药工业研究院有限公司 | 一种靶向psca的纳米抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4404381B2 (ja) * | 1997-03-10 | 2010-01-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｐｓｃａ：前立腺幹細胞抗原 |
| US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| KR100490077B1 (ko) * | 1999-10-29 | 2005-05-17 | 제넨테크, 인크. | 항-전립선 줄기세포 항원 (ｐｓｃａ) 항체 조성물 및 그의사용 방법 |
| US8076459B2 (en) * | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| RU2381234C2 (ru) * | 2004-05-28 | 2010-02-10 | Эдженсис, Инк. | Антитела и родственные молекулы, связывающиеся с белками psca |
| US8940298B2 (en) * | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| KR101837053B1 (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 |
| US20110142811A1 (en) * | 2009-12-16 | 2011-06-16 | Deutsches Krebsforschungszentrum | Measles virus for the elimination of unwanted cell populations |
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
-
2011
- 2011-06-30 DE DE102011118022.6A patent/DE102011118022B4/de not_active Expired - Fee Related
-
2012
- 2012-06-29 ES ES18207370T patent/ES2989975T3/es active Active
- 2012-06-29 EP EP18207370.0A patent/EP3505536B1/de active Active
- 2012-06-29 HR HRP20190289TT patent/HRP20190289T1/hr unknown
- 2012-06-29 HU HUE12729996A patent/HUE042008T2/hu unknown
- 2012-06-29 EP EP12729996.4A patent/EP2726507B1/de active Active
- 2012-06-29 AU AU2012277784A patent/AU2012277784B2/en not_active Ceased
- 2012-06-29 ES ES12729996T patent/ES2711978T3/es active Active
- 2012-06-29 JP JP2014517736A patent/JP2014528696A/ja active Pending
- 2012-06-29 SM SM20190085T patent/SMT201900085T1/it unknown
- 2012-06-29 US US14/129,933 patent/US9200078B2/en active Active
- 2012-06-29 WO PCT/EP2012/062716 patent/WO2013001065A1/de not_active Ceased
- 2012-06-29 PL PL12729996T patent/PL2726507T3/pl unknown
- 2012-06-29 DK DK12729996.4T patent/DK2726507T3/en active
- 2012-06-29 SI SI201231523T patent/SI2726507T1/sl unknown
- 2012-06-29 TR TR2019/01991T patent/TR201901991T4/tr unknown
- 2012-06-29 RS RS20190218A patent/RS58448B1/sr unknown
- 2012-06-29 LT LTEP12729996.4T patent/LT2726507T/lt unknown
- 2012-06-29 PT PT12729996T patent/PT2726507T/pt unknown
-
2017
- 2017-01-12 JP JP2017002983A patent/JP6549622B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-11 CY CY20191100176T patent/CY1121249T1/el unknown
- 2019-06-26 JP JP2019117977A patent/JP6886491B2/ja active Active
-
2021
- 2021-05-13 JP JP2021081553A patent/JP7341185B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE042008T2 (hu) | 2019-06-28 |
| DK2726507T3 (en) | 2019-03-11 |
| TR201901991T4 (tr) | 2019-03-21 |
| LT2726507T (lt) | 2019-04-10 |
| DE102011118022B4 (de) | 2018-01-18 |
| SI2726507T1 (sl) | 2019-05-31 |
| JP2017104113A (ja) | 2017-06-15 |
| JP2014528696A (ja) | 2014-10-30 |
| RS58448B1 (sr) | 2019-04-30 |
| EP2726507B1 (de) | 2018-11-21 |
| WO2013001065A1 (de) | 2013-01-03 |
| ES2989975T3 (es) | 2024-11-28 |
| JP2019193652A (ja) | 2019-11-07 |
| JP6549622B2 (ja) | 2019-07-24 |
| JP7341185B2 (ja) | 2023-09-08 |
| PL2726507T3 (pl) | 2019-06-28 |
| CY1121249T1 (el) | 2020-05-29 |
| AU2012277784B2 (en) | 2015-08-20 |
| EP2726507A1 (de) | 2014-05-07 |
| EP3505536B1 (de) | 2024-08-07 |
| ES2711978T3 (es) | 2019-05-08 |
| EP3505536C0 (de) | 2024-08-07 |
| DE102011118022A1 (de) | 2013-01-03 |
| AU2012277784A1 (en) | 2014-02-06 |
| JP6886491B2 (ja) | 2021-06-16 |
| US9200078B2 (en) | 2015-12-01 |
| SMT201900085T1 (it) | 2019-05-10 |
| PT2726507T (pt) | 2019-02-26 |
| US20140134155A1 (en) | 2014-05-15 |
| JP2021121201A (ja) | 2021-08-26 |
| EP3505536A1 (de) | 2019-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288203A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| SI2683406T1 (sl) | Protitelesa ANTI-CD40 in njihova uporaba | |
| IL231777B (en) | Antibodies against tl1a and uses thereof | |
| SI4403579T1 (sl) | Formulacija za protitelo anti-alfa4beta7 | |
| HRP20181515T1 (hr) | Mezenhimne stromalne stanice i upotreba povezana s njima | |
| ZA201401267B (en) | Antibodies to pcsk9 and uses thereof | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| SI2970456T1 (sl) | Postopki in sestavki za dostavo MRNA-kodiranih protiteles | |
| PL3863288T3 (pl) | Sposoby intra-predykcji i środek nośnikowy | |
| SI2812443T1 (sl) | Protitelesa CD47 in postopki za njihovo uporabo | |
| IL236874B (en) | Anti-kit antibodies and uses thereof | |
| HRP20182098T1 (hr) | Anti-angptl3 antitijela i njihove primjene | |
| HRP20170713T1 (hr) | Bispecifično anti-igf-1r i anti-erbb3 antitijelo | |
| PL2731677T3 (pl) | Przeciwciała wiążące się z OX40 i ich zastosowania | |
| PT2888284T (pt) | Anticorpos dirigidos contra haptenos de risperidona e a sua utilização | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| DK3421470T3 (da) | Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form | |
| PT2888593T (pt) | Anticorpos contra risperidona e utilizações dos mesmos | |
| HRP20171579T8 (hr) | Antigljivična sredstva i njihova upotreba | |
| PL2887952T3 (pl) | Przeciwciała przeciwko haptenom olanzapinowym i ich zastosowanie | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| HUE042008T2 (hu) | Prosztataspecifikus õssejt antigén elleni antitestek és alkalmazásuk | |
| HUE037212T2 (hu) | Anti-alfa-V integrin ellenanyag prosztatarák kezelésére | |
| IL228403A0 (en) | Compositions comprising anti-influenza antobodies and pseltamivir and uses thereof | |
| PL2771068T3 (pl) | Magnetyczny opatrunek dyfuzyjny |